Menu Back to 17th-DIA-Japan-Annual-Meeting-2020


Virtual Event

Click Here to View the Program in Japanese

Click Here to View the Program in English

Taking the theme “Beyond Innovation”, the Japan Annual Meeting 2020 will bring together academia, regulators, industry professionals, and patients from across the world to exchange information and discuss the latest trends in the discovery, development, and lifecycle management of pharmaceuticals, medical devices, and related products.

This is the largest event in the DIA Japan annual calendar and features more than 60 sessions on topics ranging from Risk Management, Patient Engagement and Pharmacovigilance to the 30th anniversary of ICH, the future of Healthcare, and the COVID-19 pandemic. Our hugely popular PMDA Town Hall DIAmond session also makes a return to the program.

This year’s Meeting will be held entirely online through a fully integrated platform offering live and on-demand content, live Q&A sessions with speakers, group and 1-2-1 networking opportunities and much more! Breaking walls and boundaries, the virtual platform will enable you to join the event from wherever you may be and to connect with fellow professionals from across the world.

We look forward to seeing you there!

Event Concept

Amidst the backdrop of the fourth industrial revolution, recent years have seen the launch of initiatives related to various innovations that will create new value and bring about major changes for our society. These innovations are an outcome of the creation and application of new techniques and technologies exemplified by the use of artificial intelligence, big data, and medical and genomic information in various fields, including research and development and lifecycle management of medical devices.

Currently, the global COVID-19 pandemic has reaffirmed the importance of the role played by medical products in providing treatment and medications to support the health and safety of people everywhere. At the same time however, efforts to take on new challenges aimed at creating new innovations that break away from conventional wisdom are underway around the globe.

As society adapts to the ongoing presence of COVID-19, it is becoming more and more important that we actively seek to learn the latest technologies and initiatives that will underpin various innovations, consider how our jobs will change and how we should reimagine those jobs moving forward, and develop the skills and mindset that will allow us to respond and adapt to these major changes. But we should also ask ourselves: do the new values and changes brought about through innovation really play a role in improving the health and welfare of patients? Perhaps it’s time for each and every stakeholder to return to the starting line and chart a path forward together.

With the theme of “Beyond Innovation”, the 17th DIA Japan Annual Meeting offers programs that are based on session proposals submitted by DIA members in an open call for submissions. We hope these will be attractive and informative for participants. In addition to a commemorative address marking 30 years of ICH activities, there will be lectures covering patient-focused drug development, overcoming drug-induced illnesses, international contributions to drug development, and the future of healthcare. Additionally, the hugely popular PMDA town hall will once again be held this year. We hope this event serves to provide a space where stakeholders—including patients—from industry, government, and academia can learn the latest information and enjoy interactive discussions.

Program Committee

  • Yuji  Kumagai, MD, PhD
    Yuji Kumagai, MD, PhD Professor, Kitasato Clinical Research Center
    Kitasato University Hospital, Japan
  • Keiichi  Inaizumi, MSc
    Keiichi Inaizumi, MSc Japan Clinical Project Manager, Clinical Operations and Compliance 1
    Pfizer R&D Japan, Japan
  • Taro  Amagasaki, PhD
    Taro Amagasaki, PhD Head, Analytics Japan
    Novartis Pharma K.K., Japan
  • Nobuyuki  Hanamura, PhD, MBA
    Nobuyuki Hanamura, PhD, MBA Senior Director, Clinical Development Strategy & Solutions
  • Toshiko  Ishibashi, PhD, RN
    Toshiko Ishibashi, PhD, RN Associate Director,Oncology Medical Science Department
    Daiichi Sankyo Co., Ltd., Japan
  • Kazuhiko  Ishida, MSc, RPh
    Kazuhiko Ishida, MSc, RPh
    Astellas Pharma Inc., Japan
  • Yayoi  Kitawaki, MS
    Yayoi Kitawaki, MS Senior Japan Program Head, Oncology Development Unit, Japan Development
    Novartis Pharma K.K., Japan
  • Yoshiko  Komuro, PhD
    Yoshiko Komuro, PhD Inspection Director in Office of Non-clinical and Clinical Compliance
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Takashi  Moriya, PhD, MBA
    Takashi Moriya, PhD, MBA Director
    Janssen Pharmaceutical K.K., Japan
  • Sumimasa  Nagai, MD, PhD
    Sumimasa Nagai, MD, PhD Institute for Advancement of Clinical and Translational Science(iACT)
    Kyoto University Hospital, Japan
  • Shinichi  Nishiuma, MD
    Shinichi Nishiuma, MD Head of Oncology Medical Science, Japan medical
    Bristol-Myers Squibb K.K., Japan
  • Mika  Ogasawara
    Mika Ogasawara Quality Lead, Biometrics and Data Management
    Pfizer R&D Japan, Japan
  • Goshi  Ozawa, MS
    Goshi Ozawa, MS Executive Officer
    Real World Data, Co., Japan
  • Keiko  Tsumori
    Keiko Tsumori Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
    MSD K.K., Japan
  • Junichi  Nishino, MSc, RPh
    Junichi Nishino, MSc, RPh Head, Regulatory Affairs Department
    Otsuka Pharmaceutical Co., Ltd., Japan
  • Hironobu  Saito, PhD
    Hironobu Saito, PhD Corporate Officer /Head of Medical Affairs Div.
    Daiichi Sankyo Co., Ltd., Japan
  • Junko  Sato, PhD
    Junko Sato, PhD Director, Office of International Programs
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Takashi  Sato, MSc, PMP
    Takashi Sato, MSc, PMP Manager, Project Management Group, Development Unit
    Kyowa Kirin Co., Ltd., Japan
  • Atsushi  Tsukamoto, PhD, MSc
    Atsushi Tsukamoto, PhD, MSc Vice President, Ne Drug Regulatory Affairs Department
    Daiichi Sankyo Company, Limited, Japan
Load More

Contact us